Search company, investor...

Argolyn Bioscience

argolynbioscience.com

Founded Year

2002

Stage

Unattributed VC | Alive

Total Raised

$15.8M

Last Raised

$15.8M | 15 yrs ago

About Argolyn Bioscience

Argolyn Bioscience is a privately held biopharmaceutical company dedicated to discovering and developing novel peptide drug candidates to treat psychosis, pain, and other serious diseases and disorders. Its most advanced development candidate is ABS201, a first-in-class peptide derivative currently in preclinical development for the treatment of schizophrenia.

Headquarters Location

2530 Meridian Parkway Suite 200

Durham, North Carolina, 27713,

United States

919-806-4634

Missing: Argolyn Bioscience's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Argolyn Bioscience's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Argolyn Bioscience

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Argolyn Bioscience is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Argolyn Bioscience Frequently Asked Questions (FAQ)

  • When was Argolyn Bioscience founded?

    Argolyn Bioscience was founded in 2002.

  • Where is Argolyn Bioscience's headquarters?

    Argolyn Bioscience's headquarters is located at 2530 Meridian Parkway, Durham.

  • What is Argolyn Bioscience's latest funding round?

    Argolyn Bioscience's latest funding round is Unattributed VC.

  • How much did Argolyn Bioscience raise?

    Argolyn Bioscience raised a total of $15.8M.

  • Who are the investors of Argolyn Bioscience?

    Investors of Argolyn Bioscience include InterSouth Partners, Quaker BioVentures, Amgen Ventures, SC Launch, South Carolina Research Authority and 3 more.

  • Who are Argolyn Bioscience's competitors?

    Competitors of Argolyn Bioscience include ChemoCentryx, Apitope, Ocera Therapeutics, BioMarck Pharmaceuticals, Raptor Pharmaceutical Corp. and 14 more.

Compare Argolyn Bioscience to Competitors

B
BrainCells

BrainCells is a biopharmaceutical company focused on the development of small molecule therapeutics for diseases of the central nervous system (CNS). The company's technology platform is based on research in the field of neurogenesis and recent discoveries linking neurogenesis to CNS disease states. BCI is using its neurogenesis technology platform to identify clinical-stage compounds, targets and compounds optimal for CNS indications. BCI is building a pipeline of clinical-stage programs to address unmet medical needs in the treatment of mood disorders, psychoses, cognition, brain repair syndromes and other CNS disorders.

Oligomerix Logo
Oligomerix

Oligomerix is a clinical-stage biotechnology company. It focuses on developing disease-modifying therapeutics for neurodegenerative diseases characterized by the aberrant tau protein, ranging from tauopathies such as progressive supranuclear palsy and frontotemporal dementia to Alzheimer’s disease. The firm serves clients in the healthcare sector. Oligomerix was founded in 2006 and is based in West Harrison, New York.

B
Bikam Pharmaceuticals

BIKAM Pharmaceuticals, Inc. is an early stage biopharmaceutical company focusing upon the discovery and development of small molecule therapeutics for the treatment of ophthalmic diseases and disorders, including retinitis pigmentosa. Worldwide, there are approximately 1.5 million people which suffer from retinitis pigmentosa (RP), a hereditary disease which leads to blindness. As its initial priority, the company is pursuing the discovery of compounds based on a novel mechanism of action identified by the company's founder, Dr. Shalesh Kaushal. BIKAM has an experienced management team with a strong track record in pharmaceutical drug discovery dedicated to expanding these findings and others from the Kaushal lab to create potential therapeutics to prevent blindness.

Protemix Logo
Protemix

Protemix is a biopharmaceutical company that discovers, develops and commercializes drug therapies for the prevention and treatment of cardiovascular disease, diabetes and other metabolic disorders and complications.

S
Sound Pharmaceuticals

Sound Pharmaceuticals (SPI) is a biopharmaceutical company that develops prescription drugs that will enable doctors and patients to prevent and treat hearing loss, a disease that affects over 30 to 40 million Americans. It was founded in 2002 and is based in Seattle, Washington.

B
BioMarck Pharmaceuticals

BioMarck Pharmaceuticals is a biopharmaceutical company dedicated to the discovery and development of drugs for the treatment of pulmonary diseases and disorders associated with the over-secretion of mucus and pulmonary inflammation. In developing its lead compound, BIO-11006 Inhalation Solution, BioMarck has chosen chronic obstructive pulmonary disease (specifically chronic bronchitis) as its first target, but other diseases including asthma, and cystic fibrosis are later disease targets. BIO-11006 Inhalation Solution works by a novel dual mechanism; it inhibits both the secretion of mucus in the lungs and pulmonary inflammation. These aspects of BIO-11006 Inhalation Solution have been demonstrated in several different animal models. In addition, BioMarck has completed a full panel of preclinical safety studies, has an active IND with the FDA, has completed two BIO-11006 in Phase 1 clinical studies, and is currently conducting a Phase 2 study of the efficacy of BIO-11006 in COPD patients.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.